Xenetic Biosciences (XBIO) Total Liabilities (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Total Liabilities came in at $958239.0 in Q1 2026, up 43.46% YoY from $667927.0 in Q1 2025, and down 1.01% on a QoQ basis from $968025.0 in Q4 2025.
Xenetic Biosciences (XBIO) Total Liabilities (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Total Liabilities data on file, last reported at $958239.0 in Q1 2026.
- Quarterly Total Liabilities rose 43.46% year-over-year to $958239.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $958239.0 (up 43.46% YoY) and the FY2025 annual result came in at $968025.0, up 8.25% from the prior year.
- Total Liabilities retreated to $958239.0 in Q1 2026, from $968025.0 in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $1.6 million in Q2 2024 to a low of $667927.0 in Q1 2025.
- A 5-year average of $993493.5 and a median of $968025.0 in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 82.21% — and 2025, when it sank 43.09%.
- Tracing XBIO's Total Liabilities over 5 years: stood at $1.1 million in 2022, then retreated by 24.56% to $809585.0 in 2023, then increased by 10.46% to $894263.0 in 2024, then climbed by 8.25% to $968025.0 in 2025, then decreased by 1.01% to $958239.0 in 2026.
- The last three Total Liabilities figures came in at $958239.0 (Q1 2026), $968025.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 894,977.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 894,977.00 |
| Mar 31, 2026 | 958,239.00 |
| Dec 31, 2025 | 968,025.00 |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 903,430.00 |
| Mar 31, 2025 | 667,927.00 |
| Dec 31, 2024 | 894,263.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 716,494.00 |
| Dec 31, 2023 | 809,585.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 871,315.00 |
| Mar 31, 2023 | 856,365.00 |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.12 Mn |